Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BCL2L11 | O43521 | 2/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15562602 | 0.83 | GLA (0.42) | ALDH1A1LMNAGLAMAPK1DPP4 | |
| SCHEMBL6027707 | 0.80 | ALDH1A1 (0.51) | ALDH1A1LMNAGLAMAPK1SRC | |
| SCHEMBL25014093 | 0.78 | ALDH1A1 (0.42) | ALDH1A1BCL2L11BCL2L1MCL1GLA | |
| SCHEMBL4134269 | 0.77 | DPP4 (0.43) | ALDH1A1LMNAGLAMAPK1DPP4 | |
| SCHEMBL12673478 | 0.77 | HSP90AB1 (0.43) | ALDH1A1BCL2L11BCL2L1MCL1GLA | |
| SCHEMBL15775419 | 0.76 | ALDH1A1 (0.43) | ALDH1A1LMNAKDM4EMAPK1DPP4 | |
| SCHEMBL20615682 | 0.76 | DPP4 (0.40) | ALDH1A1LMNAGLADPP4SRC | |
| SCHEMBL28497312 | 0.75 | MITF (0.39) | ALDH1A1LMNABCL2L11BCL2L1MCL1 | |
| SCHEMBL4553447 | 0.75 | SRC (0.49) | BCL2L11BCL2L1MCL1SRCNR1H4 | |
| SCHEMBL23038456 | 0.74 | ALDH1A1 (0.41) | ALDH1A1BCL2L11BCL2L1MCL1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200383985-A1 | Inhibitors of Protease Activated Receptor-2 | MONASH UNIVERSITY (AU) | 2020-12-10 | — | — | US | disclosed |
| US-20200383985-A1 | Inhibitors of Protease Activated Receptor-2 | MONASH UNIVERSITY (AU) | 2020-12-10 | — | — | US | disclosed |
| EP-3727386-A1 | INHIBITORS OF PROTEASE ACTIVATED RECEPTOR-2 | Takeda Pharmaceutical Company Limited (JP) | 2020-10-28 | — | — | EP | disclosed |
| CN-111698991-A | Inhibitors of protease activated receptor-2 | 武田药品工业株式会社 | 2020-09-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383985-A1 | Inhibitors of Protease Activated Receptor-2 | F2RL1, F2R, F2RL3 | ALDH1A1 4363/4885LMNA 1431/4885BCL2L11 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.